India's Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease clinical testing for the drugs that make up more than 60% of its revenue, a top executive said on Wednesday.
from NDTV News Search Records Found 1000 https://ift.tt/5AUu2Ky
Friday, 14 November 2025
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment